Enveric Biosciences (ENVB) EPS (Diluted) Growth (1y) (2015 - 2026)
Enveric Biosciences (ENVB) EPS (Diluted) Growth (1y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 8.02% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -4.52% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 96.09% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 7.59% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 144.25% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 315.14% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -147.33% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 96.41% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -11.18% |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - | 93.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 92.58% |
| Dec 31, 2025 | 83.97% |
| Sep 30, 2025 | 74.91% |
| Jun 30, 2025 | 73.88% |
| Mar 31, 2025 | 86.80% |
| Dec 31, 2024 | 73.72% |
| Sep 30, 2024 | 81.63% |
| Jun 30, 2024 | 91.84% |
| Mar 31, 2024 | 73.42% |
| Dec 31, 2023 | 73.86% |
| Sep 30, 2023 | 10.47% |
| Jun 30, 2023 | -11.40% |
| Mar 31, 2023 | 98.65% |
| Dec 31, 2022 | 99.62% |
| Sep 30, 2022 | 98.58% |
| Jun 30, 2022 | 92.06% |
| Mar 31, 2022 | 38.87% |
| Dec 31, 2021 | -1,546.63% |
| Sep 30, 2021 | -153.35% |
| Jun 30, 2021 | 63.98% |